SCHEMBL25366331

SCHEMBL25366331

NNC(=O)c1c(F)ccc(F)c1C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.41
ALDH1A1 P00352 4/20 0.41
KDM4E B2RXH2 4/20 0.41
L3MBTL1 Q9Y468 3/20 0.41
LMNA P02545 2/20 0.41
ITGB2 P05107 2/20 0.39
ICAM1 P05362 2/20 0.39
ITGAL P20701 2/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
MPO P05164 2/20 0.38
CYP3A4 P08684 2/20 0.38
BLM P54132 2/20 0.38
KDM5A P29375 1/20 0.38
GFER P55789 1/20 0.38
PMP22 Q01453 1/20 0.38
HIF1A Q16665 1/20 0.38
CES2 O00748 1/20 0.37
CES1 P23141 1/20 0.37
NSD2 O96028 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30048528 0.82 CES2 (0.50) ALDH1A1KDM4ECES2CES1TDP1
SCHEMBL3309453 0.82 CES2 (0.50) ALDH1A1KDM4ECES2CES1TDP1
SCHEMBL2645530 0.81 ALDH1A1 (0.42) MAPTALDH1A1KDM4EL3MBTL1LMNA
SCHEMBL1127907 0.78 CES2 (0.56) MAPTALDH1A1L3MBTL1LMNAITGB2
SCHEMBL25363190 0.77 CES2 (0.50) MAPTALDH1A1L3MBTL1ITGB2ICAM1
SCHEMBL29442184 0.76 CES2 (0.41) MAPTL3MBTL1ITGB2ICAM1ITGAL
SCHEMBL23631778 0.76 CES2 (0.41) MAPTL3MBTL1ITGB2ICAM1ITGAL
SCHEMBL28723694 0.74 KDM4E (0.42) MAPTALDH1A1KDM4EL3MBTL1LMNA
SCHEMBL21750024 0.74 KEAP1 (0.45) MAPTALDH1A1KDM4ELMNABLM
SCHEMBL29970839 0.73 CES2 (0.56) MAPTALDH1A1L3MBTL1LMNAITGB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250154130-A1 NOVEL THR BETA ANALOGS AND USES THEREOF LSI FINANCING LLC, AS ADMINISTRATIVE AGENT 2025-05-15 US disclosed
EP-4476209-A1 THR BETA ANALOGS AND USES THEREOF Madrigal Pharmaceuticals, Inc. (US) 2024-12-18 EP disclosed
WO-2023154842-A1 THR BETA ANALOGS AND USES THEREOF MADRIGAL PHARMACEUTICALS, INC. (US) 2023-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250154130-A1 NOVEL THR BETA ANALOGS AND USES THEREOF THRB, THRA, TSHR MAPT 2343/4885ALDH1A1 2389/4885KDM4E 4475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.